|
|
| (2 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
|
| |
|
| ==Crystal structure of Antigen 85C-H260Q mutant== | | ==Crystal structure of Antigen 85C-H260Q mutant== |
| <StructureSection load='4qe3' size='340' side='right' caption='[[4qe3]], [[Resolution|resolution]] 1.35Å' scene=''> | | <StructureSection load='4qe3' size='340' side='right'caption='[[4qe3]], [[Resolution|resolution]] 1.35Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
| <table><tr><td colspan='2'>[[4qe3]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QE3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QE3 FirstGlance]. <br> | | <table><tr><td colspan='2'>[[4qe3]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis_H37Rv Mycobacterium tuberculosis H37Rv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QE3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4QE3 FirstGlance]. <br> |
| </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1N7:CHAPSO'>1N7</scene>, <scene name='pdbligand=ACY:ACETIC+ACID'>ACY</scene></td></tr> | | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.351Å</td></tr> |
| <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4qdo|4qdo]], [[4qdt|4qdt]], [[4qdu|4qdu]], [[4qdx|4qdx]], [[4qdz|4qdz]], [[4qek|4qek]]</td></tr> | | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1N7:CHAPSO'>1N7</scene>, <scene name='pdbligand=ACY:ACETIC+ACID'>ACY</scene></td></tr> |
| <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qe3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qe3 OCA], [http://pdbe.org/4qe3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4qe3 RCSB], [http://www.ebi.ac.uk/pdbsum/4qe3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4qe3 ProSAT]</span></td></tr> | | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4qe3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qe3 OCA], [https://pdbe.org/4qe3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4qe3 RCSB], [https://www.ebi.ac.uk/pdbsum/4qe3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4qe3 ProSAT]</span></td></tr> |
| </table> | | </table> |
| == Function == | | == Function == |
| [[http://www.uniprot.org/uniprot/A85C_MYCTU A85C_MYCTU]] The antigen 85 proteins (FbpA, FbpB, FbpC) are responsible for the high affinity of mycobacteria to fibronectin, a large adhesive glycoprotein, which facilitates the attachment of M.tuberculosis to murine alveolar macrophages (AMs). They also help to maintain the integrity of the cell wall by catalyzing the transfer of mycolic acids to cell wall arabinogalactan and through the synthesis of alpha,alpha-trehalose dimycolate (TDM, cord factor). They catalyze the transfer of a mycoloyl residue from one molecule of alpha,alpha-trehalose monomycolate (TMM) to another TMM, leading to the formation of TDM.<ref>PMID:1830294</ref> <ref>PMID:9162010</ref> | | [https://www.uniprot.org/uniprot/A85C_MYCTU A85C_MYCTU] The antigen 85 proteins (FbpA, FbpB, FbpC) are responsible for the high affinity of mycobacteria to fibronectin, a large adhesive glycoprotein, which facilitates the attachment of M.tuberculosis to murine alveolar macrophages (AMs). They also help to maintain the integrity of the cell wall by catalyzing the transfer of mycolic acids to cell wall arabinogalactan and through the synthesis of alpha,alpha-trehalose dimycolate (TDM, cord factor). They catalyze the transfer of a mycoloyl residue from one molecule of alpha,alpha-trehalose monomycolate (TMM) to another TMM, leading to the formation of TDM.<ref>PMID:1830294</ref> <ref>PMID:9162010</ref> |
| <div style="background-color:#fffaf0;">
| |
| == Publication Abstract from PubMed ==
| |
| The rise of multidrug and totally drug-resistant tuberculosis (TB) and the association with an increasing number of HIV-positive patients developing TB emphasizes the necessity to find new antitubercular targets and drugs. The antigen 85 (Ag85) complex from Mycobacterium tuberculosis plays important roles in the biosynthesis of major components of the mycobacterial cell envelope. For this reason, Ag85 has emerged as an attractive drug target. Recently, ebselen was identified as an effective inhibitor of the Ag85 complex through covalent modification of a cysteine residue proximal to the Ag85 active site and is therefore a covalent, allosteric inhibitor. To expand the understanding of this process, we have solved the X-ray crystal structures of Ag85C covalently modified with ebselen and other thiol-reactive compounds, p-chloromercuribenzoic acid and iodoacetamide, as well as the structure of a cysteine to glycine mutant. All four structures confirm that chemical modification or mutation at this particular cysteine residue leads to the disruption of the active site hydrogen-bonded network essential for Ag85 catalysis. We also describe X-ray crystal structures of Ag85C single mutants within the catalytic triad and show that a mutation of any one of these three residues promotes the same conformational change observed in the cysteine modified forms. These results provide evidence for active site dynamics that may afford new strategies for the development of selective and potent Ag85 inhibitors.
| |
| | |
| Inactivation of the Mycobacterium tuberculosis Antigen 85 complex by covalent, allosteric inhibitors.,Favrot L, Lajiness DH, Ronning DR J Biol Chem. 2014 Jul 14. pii: jbc.M114.582445. PMID:25028518<ref>PMID:25028518</ref>
| |
| | |
| From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
| |
| </div>
| |
| <div class="pdbe-citations 4qe3" style="background-color:#fffaf0;"></div>
| |
|
| |
|
| ==See Also== | | ==See Also== |
| *[[Antigen 85|Antigen 85]] | | *[[Antigen 85 3D structures|Antigen 85 3D structures]] |
| == References == | | == References == |
| <references/> | | <references/> |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
| [[Category: Favrot, L]] | | [[Category: Large Structures]] |
| [[Category: Lajiness, D H]] | | [[Category: Mycobacterium tuberculosis H37Rv]] |
| [[Category: Ronning, D R]] | | [[Category: Favrot L]] |
| [[Category: Mycolyltransferase/diacylglycerol acyltransferase]] | | [[Category: Lajiness DH]] |
| [[Category: Transferase]] | | [[Category: Ronning DR]] |